Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 8/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2844807 | 1.00 | FOLH1 (0.54) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| Hydrochloric Acid SCHEMBL25283310 | 1.00 | FOLH1 (0.54) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| Hydrochloric Acid SCHEMBL29268897 | 1.00 | FOLH1 (0.54) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| Hydrochloric Acid SCHEMBL8919770 | 1.00 | FOLH1 (0.54) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL168589 | 0.98 | FOLH1 (0.56) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL164121 | 0.98 | FOLH1 (0.56) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL165084 | 0.98 | FOLH1 (0.56) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| Bromide SCHEMBL6933931 | 0.96 | FOLH1 (0.54) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| Methane SCHEMBL15135721 | 0.96 | FOLH1 (0.54) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| Methane SCHEMBL15135720 | 0.96 | FOLH1 (0.54) | FOLH1GSRRNPEPSLC6A5MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131011-A1 | Anti-Viral Therapeutic Peptides, Conjugates, and Methods of Use Thereof | DECOY THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260041714-A1 | CROSS-LINKING AGENTS AND ASSOCIATED METHODS | UNIV UTAH RES FOUND (US) | 2026-02-12 | — | — | US | disclosed |
| WO-2025231157-A2 | NEW ANTI-VIRAL THERAPEUTIC PEPTIDES, CONJUGATES, AND METHODS OF USE THEREOF | DECOY THERAPEUTICS INC. (US) | 2025-11-06 | — | — | WO | disclosed |
| EP-3746467-B1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2025-10-08 | — | — | EP | disclosed |
| CN-111770934-B | Modified lipidated relaxin B chain peptides and therapeutic uses thereof | 赛诺菲 | 2024-10-18 | — | — | CN | disclosed |
| WO-2023121955-A9 | THE METHODS OF AND COMPOSITIONS FOR TREATING OBESITY, OBESITY-RELATED DISEASES OR CANCERS USING A N6-METHYLLYSINE/L-LYSINE MIXTURE | TAINNOVATION INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20240218042-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2024-07-04 | — | — | US | disclosed |
| EP-4324454-A2 | CROSS-LINKING AGENTS AND ASSOCIATED METHODS | University of Utah Research Foundation (US) | 2024-02-21 | — | — | EP | disclosed |
| EP-3426262-B1 | CROSS-LINKING AGENTS AND ASSOCIATED METHODS | UNIV UTAH RES FOUND (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11725036-B2 | Modified lipidated relaxin B chain peptides and their therapeutic use | SANOFI (FR) | 2023-08-15 | — | — | US | disclosed |
| WO-2023121955-A1 | THE METHODS OF AND COMPOSITIONS FOR TREATING OBESITY, OBESITY-RELATED DISEASES OR CANCERS USING A N6-METHYLLYSINE/L-LYSINE MIXTURE | TAINNOVATION INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-2576638-A2 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | Syndevrx, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011150022-A2 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-0904401-A4 | — | — | 1999-05-12 | — | — | EP | disclosed |
| EP-0904401-A1 | COMBINATORIAL HYDROXYPROPYLAMINE LIBRARY | PHARMACOPEIA, INC. (US) | 1999-03-31 | — | — | EP | disclosed |
| WO-1997027315-A1 | COMBINATORIAL HYDROXYPROPYLAMINE LIBRARY | PHARMACOPEIA, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| US-5631031-A | FOOD SUPPLEMENTS FOR RUMINANTS AND HUMANS AS CALCIUM SALTS | MEADE THOMAS L (US) | 1997-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041714-A1 | CROSS-LINKING AGENTS AND ASSOCIATED METHODS | KCNK17, KCNJ2, KCNK2 | CA2 2131/4885FOLH1 4812/4885GSR 3412/4885 |
| US-20240218042-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | RXFP1, RXFP2, RXFP4 | CA2 1247/4885FOLH1 2255/4885GSR 3529/4885 |
| US-20260131011-A1 | Anti-Viral Therapeutic Peptides, Conjugates, and Methods of Use Thereof | SARS1, HM13, PTMS | CA2 2618/4885FOLH1 126/4885GSR 2193/4885 |
| US-11725036-B2 | Modified lipidated relaxin B chain peptides and their therapeutic use | SCTR, RXFP1, RXFP3 | CA2 1411/4885FOLH1 683/4885GSR 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.